Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2024-02-07
2024-03-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Noise-Induced Hearing Loss
NCT01022710
Aetiology of Asymmetrical Hearing Loss: A Retro-spective Study Thesis Submitted for Partial Fulfillment of Master Degree in Audio-Vestibular Medicine
NCT05543135
Hearing Loss and Osteoporosis
NCT03895333
Retrospective Analysis of Long-term Speech Performance in Cochlear Implant Recipients Using Electro-acoustic Stimulation
NCT06301568
Healthful Diets and Risk of Hearing Loss
NCT03351023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Individuals with A Rh (+) blood group
Individuals with normal hearing and whose blood group was previously determined as A Rh (+) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with A Rh (-) blood group
Individuals with normal hearing and whose blood group was previously determined as A Rh (-) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with B Rh (+) blood group
Individuals with normal hearing and whose blood group was previously determined as B Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with B Rh (-) blood group
Individuals with normal hearing and whose blood group was previously determined as B Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with AB Rh (+) blood group
Individuals with normal hearing and whose blood group was previously determined as AB Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with AB Rh (-) blood group
Individuals with normal hearing and whose blood group was previously determined as AB Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with O Rh (+) blood group
Individuals with normal hearing and whose blood group was previously determined as O Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Individuals with O Rh (-) blood group
Individuals with normal hearing and whose blood group was previously determined as O Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Otoacoustic emissions (non-invasive)
There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having a blood group card obtained from health institutions
18 Years
26 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul University - Cerrahpasa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eyyup Kara
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eyyup Kara, PhD
Role: PRINCIPAL_INVESTIGATOR
Istanbul University - Cerrahpasa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eyyup KARA
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E-74555795-050.04-941208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.